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HIV-1 gp41 Fusion Intermediate: A Target for
HIV Therapeutics
Chungen Pan1,2, Shuwen Liu3, Shibo Jiang1,3*
Human immunodeficiency virus (HIV)-1 infection is initiated by the binding of gp120 envelope glyco-
protein to its cell receptor (CD4) and a coreceptor (CXCR4 or CCR5), followed by a series of conforma-
tional changes in the gp41 transmembrane subunit. These changes include insertion of fusion peptide
into the target cell membrane and association of C-heptad repeat (CHR) peptide with the N-heptad repeat
(NHR) trimer, a pre-hairpin fusion intermediate. A stable six-helix bundle core is then formed, bringing
the viral envelope and target cell membrane into close proximity for fusion. Peptides derived from the
CHR region, such as T20 and C34, inhibit HIV-1 fusion by interacting with the gp41 fusion intermediate.
A number of anti-HIV-1 peptides and small molecule compounds targeting the gp41 NHR-trimer have
been identified. By combining HIV fusion/entry inhibitors targeting different sites in the gp41 fusion 
intermediate, a potent synergistic effect takes place, resulting in a potential new therapeutic strategy for the
HIV infection/AIDS. Here, we present an overview of the current development of anti-HIV drugs, particu-
larly those targeting the gp41 fusion intermediate. [J Formos Med Assoc 2010;109(2):94–105]
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Since acquired immunodeficiency syndrome
(AIDS) was first reported in 1981, almost 60 mil-
lion people worldwide have been infected by
human immunodeficiency virus (HIV), the cau-
sative agent for AIDS; and cumulatively 25 mil-
lion patients have died from AIDS.1–3 By now, 28
anti-HIV drugs, including 15 reverse transcrip-
tase inhibitors (RTIs) and 10 protease inhibitors
(PIs), have been licensed by the US Food and
Drug Administration (FDA) for treatments of HIV
infection/AIDS.4 Clinical application of these anti-
retroviral drugs in combinations (known as highly
active antiretroviral therapy) have been shown 
to reduce the morbidity and mortality of HIV 
infection/AIDS significantly.5 However, because of
the emergence of multidrug resistance to RTIs and
PIs, many patients failed to respond to the current
antiretroviral therapeutics.6–8 Therefore, it is essen-
tial to develop new anti-HIV drugs, particularly tar-
geting the fusion and entry steps of HIV infection.
HIV gp41 Fusion Intermediate
The HIV envelope (Env) glycoprotein surface
subunit gp120 is responsible for virus binding to
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its cell receptors, CD4; while its transmembrane
subunit gp41 mediates virus fusion with and
entry into the host cell. The gp41 consists of an
extracellular domain, a transmembrane domain,
and a cytoplasm domain. The extracellular do-
main contains a fusion peptide, a N-terminal
heptad repeat (NHR), a loop region, a C-terminal
heptad repeat (CHR), and a membrane-proximal
external region (MPER) (Figure 1A). The NHR
contains a pocket-forming domain (PFD), a 
heptad repeat (HR) sequence, and a glycine-
isoleucine-valine (GIV) motif. CHR contains a
pocket-binding domain (PBD) and an HR se-
quence. MPER contains a tryptophan-rich do-
main (TRD) or lipid-binding domain (LBD).9–13
Both NHR and CHR regions contain hydropho-
bic 4-3 HR sequences that can form coiled-coil
structure (Figure 1B).14
HIV infection is initiated by the binding of
gp120 to its primary receptor, CD4, and a chem-
okine coreceptor (CXCR4 or CCR5) on the host
cell, triggering a series of conformational changes
in gp41 and allowing the fusion peptide of gp41
inserts into the cell membrane, and the pre-hairpin
fusion intermediate NHR-trimer forms. In each
groove of the NHR-trimer, there is a highly con-
served hydrophobic deep pocket formed by the
PFD, which plays a critical role in maintaining
the stability of the six-helix bundle (6-HB) and
viral fusion.9,15,16 Subsequently, three molecules
of CHR pack obliquely in an anti-parallel manner
into the highly conserved hydrophobic grooves
on the surface of the NHR-trimer to form a stable
gp41 6-HB core structure,8 which brings the viral
and host cell membranes into proximity for
virus-cell fusion.19 Therefore, any molecules that
block the 6-HB formation may inhibit the viru-
cell fusion.10,20,21
Anti-HIV Peptides Targeting the gp41
Fusion Intermediate
In the early 1990s, our group discovered the first
highly potent anti-HIV peptide, SJ-2176, which
was derived from the HIV-1 gp41 CHR region
(a.a. 630–659, the residue numbers correspond
to their positions in gp160 of HIV-1HXB2).22,23
Later, Wild et al reported another CHR peptide,
T20 (a.a. 638–673), with potent inhibitory activ-
ity against HIV fusion.24 Using the protein dissec-
tion strategy, Lu et al identified a series of NHR
peptides, including N51 (a.a. 540–590), N36 (a.a.
546–581), and N34 (a.a. 546–579), as well as
CHR peptides, such as C43 (a.a. 624–666), C34
(a.a. 628–661), and C28 (a.a. 628–655) (Figure
1A).14,25,26 C34 exhibits higher anti-HIV potency
than SJ-2176 and T20.5
Crystallographic studies and biochemical an-
alyses revealed that both SJ-2176 and C34 contain
the PBD and HR sequence, and inhibit HIV-1 
Env-mediated membrane fusion by interacting
with the pocket region and HR sequence in the
viral gp41 NHR and blocking gp41 6-HB core for-
mation, a critical step in virus-cell fusion.17–19,21,27
T20, which contains the TRD/LBD but lacks the
PBD, inhibits HIV fusion by interacting with the
viral gp41 NHR domain through its N-terminal
HR sequence and binding to the lipid mem-
brane of the target cell via its C-terminal LBD
(Figure 1).11,12,28,29
T20 (also called enfuvirtide or Fuzeon®) was
developed by Trimeris, Inc. (Durham, NC, USA)
and Hoffmann-La Roche, Inc. (Nutley, NJ, USA)
as the first HIV fusion/entry inhibitors. T20 have
been licensed by the US FDA since 2003 for the
treatment of HIV patients who failed to respond
to the current antiretroviral therapeutics.30 T20 
is effective against a broad spectrum of HIV-1
strains, including those resistant to RTIs and PIs.
However, T20 could induce drug-resistant muta-
tions in the viral gp41 NHR region, resulting in
an increased number of patients failing to re-
spond to T20.31–34 In addition, T20 has several
other pitfalls, including low potency and short
half-life in vivo.35 To address these problem, 
T20 analogous peptides or recombinant proteins
containing CHR sequence with improved pro-
duction efficiency, half-life, and antiviral potency
against a broad spectrum of HIV-1 strains, 
including the T20-resistant variants, have been
developed.
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Figure 1. Schematic representation of the HIV-1 gp41 fusion intermediate and its target sites for anti-HIV therapeutics.
(A) Schematic view of the HIV-1HXB2 gp41 molecule and sequences of the NHR- and CHR-peptides. PFD in the NHR,
the QIWNNMT-motif and PBD in CHR, as well as LBD in the MPER are highlighted in green, pink, blue, and red, respec-
tively. (B) Interaction between the NHR- and CHR-peptides. The dashed lines between the NHR and CHR domains 
indicate the interaction between the residues located at the e, g and a, d positions in the helical wheels of the NHR and
CHR domains, respectively. The association between NHR and CHR results in formation of the 6-HB core, while the in-
teraction between PFD in the NHR and PBD in the CHR is critical for stabilization of 6-HB. (C) The target sites in the
gp41 fusion intermediate for HIV fusion/entry inhibitors. FP = fusion peptide; NHR = N-terminal heptad repeat; CHR = C-
terminal heptad repeat; MPER=membrane-proximal external region; PFD=pocket-forming domain; PBD=pocket-binding
domain; LBD = lipid-binding domain; HB = helix bundle; TM = transmembrane domain; CP = cytoplasmic domain.
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T1249, designed by Trimeris Inc. as the second-
generation HIV fusion inhibitor, is a 39-mer 
peptide consisting of a PBD, a CHR-binding 
domain, and a TRD (Figure 1). Pre-clinical and
clinical studies have demonstrated that T1249
has a longer half-life in primates36 and greater
anti-HIV-1 potency than T20. T1249 is active
against most T20-resistant HIV-1 variants.36–39
However, the clinical development of T1249 was
discontinued due to formulation difficulties.40
T1144 was also designed by Trimeris Inc. as
the third-generation HIV fusion inhibitor by
modifying the amino acid sequence of C38 (a.a.
626–673) to increase the helicity and 6-HB 
stability. Like C34, it contains a PBD and a HR 
sequence (Figure 1). T1144 and its analogous
peptides have shown more potent anti-HIV-1 
activity than T20 and have exhibited improved
pharmacokinetic properties.41,42 They are effec-
tive against T20-resistant virus strains with lower
chances to induce drug-resistant mutations, sug-
gesting that T1144 is an attractive candidate for
further development.
Sifuvirtide is a new generation of HIV fusion
inhibitor designed by FusoGen Pharmaceuticals
Inc. (Tianjin, China) through modification of
the CHR-peptide C36 (a.a. 627–672), based on
the 3D structural information of HIV-1 gp41 and
computer modeling analysis. Like C34 and
T1144, Sifuvirtide contains the PBD and the HR
sequence (Figure 1). We have demonstrated that
Sifuvirtide is more potent than T20 against both
primary- and laboratory-adapted HIV-1 strains
and is effective against T20-resistant virus vari-
ants. It has a longer half-life than T20.43 In the
Phase Ia clinical trial, Sifuvirtide showed good
safety, tolerability, and pharmacokinetic profiles
in healthy individuals. It is currently under Phase
II clinical development.44
CP32 is a 32-mer peptide derived from a CHR
sequence (a.a. 621–652) which contains the 
HR sequence, PBD, and a QIWNNMT motif
(Figure 1). This motif, which is located at the 
upstream region of the CHR and immediately
adjacent to the PBD, is critical for the gp41 6-HB
core stabilization.6 This peptide can interact with
the NHR-peptide T21 (a.a. 553–590)45 to form
6-HB with high thermostability (Tm = 81ºC) and
significantly inhibit the gp41 fusogenic core 
formation between the viral NHR and CHR,
thereby blocking HIV-1 Env-mediated cell-cell
fusion and HIV-1 replication. Notably, CP32 ex-
hibited potent antiviral activity against HIV-1
strains which is resistant to T20 and C34, because
it lacks the sequence that binds to GIV motif, 
the determinant of T20-resistance in NHR.46
Interestingly, further modification of CP32 re-
sults in the generation of an analogous peptide,
CP32M, which has improved thermostability
(Tm = 94°C) and enhanced antiviral potency
against HIV-1 variants resistant to T20, C34, and 
T-1249.47
SC34EK(Nle) is a C34 analogous peptide with
improved solubility and anti-HIV-1 efficacy.48 The
non-conserved residues located at the solvent-
accessible sites in the 4-3 HR sequence, including
those at the “b”, “c”, “f ”, and “g” positions in the
α-helical wheel, are restituted with the positively
and negatively charged residues (Lys and Glu, re-
spectively) at the i and i + 4 positions to intro-
duce intrahelical salt bridges, which are expected
to enhance the solubility and α-helicity of the
CHR-peptides. Indeed, SC34EK(Nle) exhibits
higher HIV fusion inhibitory activity and solu-
bility in aqueous solutions than T20 and C34.
C14 linkmid was designed based on a 14-mer
CHR-peptide, C14 (a.a. 626–639) by substituting
the residues at the “b” position (a.a. 629 and 636)
in the helical wheel with Glu and crosslinking
these residues via a (α,ω)-diaminoalkane group,
which stabilizes the helix of C14.49 This short
CHR-peptide can bind to the hydrophobic pocket
on the NHR-trimer and inhibit the HIV-1 Env-
induced cell-cell fusion with IC50 of 35 μM, while
the unmodified C14 peptide has no anti-HIV-1
activity.
D10-p1-2K, D10-p5-2K, and PIE7 are short
cyclic peptides consisting of all D-amino acid 
residues which are resistant to proteolytic enzy-
mes.50–52 As determined by X-ray crystallography
and nuclear magnetic resonance, these peptides
specifically bind to the hydrophobic pocket 
HIV-1 gp41 fusion intermediate
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presented on NHR-trimers, such as IQN17. D10-
p5-2K and PIE7 can inhibit HIV-1 infection with
IC50, ranging from low μM to nM levels. These
short D-peptides are expected to be resistant to
proteases, which may significantly increase their
serum half-lives and may be absorbed systemically
when taken orally, suggesting an anti-HIV thera-
peutic potential.
C52L is a recombinant protein consisting of the
PBD, the HR sequence and the TRD, overlapping
the gp41 CHR sequence (a.a. 624–675).53 It binds
to the gp41 NHR region and potently inhibits 
in vitro infection by diverse primary HIV-1 isolates
with nanomolar (nM) IC50 values. C52L is also very
effective against T20-resistant variants. Since it is ex-
pressed in Escherichia coli, C52L is expected to be
more economical to manufacture on a large scale
than T20-like peptides produced by chemical
synthesis and have a potential to be developed as
an effective and inexpensive microbicide for pre-
vention of sexual transmission of HIV.54
HR212, another recombinant protein expre-
ssed in E. coli, consists of two molecules of HR2-
peptide (C34: a.a. 628–661) and one molecule
of HR1-peptide (N34: a.a. 546–579) linked in
the order of HR2-HR1-HR2. In aqueous solu-
tion, HR212 can form a stable 6-HB with three
HR2-peptides exposed, which may bind to the
NHR region in the viral gp41, resulting in inhibi-
tion of gp41-mediated membrane fusion. HR212
exhibits potent inhibitory activity on infection
by primary and laboratory-adapted HIV-1 strains
with IC50 values in the nM range.55,56 These data
suggested that HR212 can be potentially devel-
oped as a therapeutic agent in a manner analo-
gous to synthetic CHR-peptides, but may be much
less expensive than the synthetic peptides since
HR212 can be easily expressed and purified from
the bacterial culture.
In the pre-hairpin fusion intermediate, the
hydrophobic face of CHR-helix is also accessible
to the peptidic HIV fusion inhibitors, such 
as T21, N51, and N36.14,17,25,46 HR121 is a re-
combinant protein containing two molecules of 
HR1-peptide N34 and one molecule of HR2-
peptide C34 connected by linkers in the order of
HR1-HR2-HR1. In aqueous solution, HR121
forms a stable 6-HB with the HR1-trimer ex-
posed, which can bind to the CHR region in the
viral gp41 and block the viral gp41 fusion core
formation. It is also effective in inhibiting HIV-1
infection, although its anti-HIV-1 potency is lower
than that of HR212.55
NCCG-gp41 was designed by linking an NHR-
peptide N35 (a.a. 546–580) to the N-terminus
of N34(L6)C28 polypeptide25 and substituting
Leu576, Gln577, and Ala578 of N35 with Cys,
Cys, and Gly, respectively.57 In NCCG-gp41, the
three N34(L6)C28 polypeptides form 6-HB
whereas the three N35 peptides form an NHR-
trimer stabilized by three intermolecular disul-
fide bonds. Like HR121, NCCG-gp41 can inhibit
HIV-1 Env-mediated membrane fusion by target-
ing the gp41 CHR-helices in the fusion interme-
diate state.
5-Helix contains three NHR-peptides N40
(a.a. 543–582) and two CHR-peptides C38 (a.a.
625–662) connected by linkers in the order of
N40-C38-N40-C38-N40.58 In aqueous solution,
it forms a stable and soluble 5-HB with one ex-
posed hydrophobic groove, which can attract
one of the viral gp41 CHR-helices to form 6-HB
core. Therefore, 5-helix exhibits highly potent anti-
HIV-1 activity with IC50 at low nM level. 5-Helix
conjugated with Pseudomonas, an exotoxin pro-
tein, can serve as a “biological missile” by spe-
cifically binding to the CHR region of the viral
gp41 on the HIV-1-infected cells, thereby killing
these infected cells with its toxin component 
or blocking fusion between HIV-1-infected and
uninfected cells.59
Virus-inhibitory peptide (VIRIP) is a 20-
mer peptide corresponding to the C-proximal 
region of a1-antitrypsin, the most abundant cir-
culating serine PIs in human blood. This peptide
inhibits infection by a wide variety of primary
HIV-1 isolates. It blocks HIV-1 fusion/entry by
interacting with the gp41 fusion peptide in the
fusion intermediate state. Changes of a few amino
acid residues in the peptide result in increase of
its ant-HIV-1 potency by two orders of magni-
tude.60 Therefore, this natural HIV fusion/entry
C. Pan, et al
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inhibitor targeting the gp41 fusion peptide may
be further developed as a new class of antiretro-
viral drugs.
Small Molecule Anti-HIV Compounds
Targeting the gp41 Fusion Intermediate
Although T20 is effective against HIV-1 strains
resistant to RTIs and PIs, it has a short half-life 
in vivo35 because the peptide can be easily degraded
by proteolytic enzymes in the blood. To main-
tain constant high concentration of T20 in vivo,
T20 must be administered by injection twice a
day at 90 mg/dose, resulting in painful injection-
site reactions in most patients and high cost to
the patients (> US$20,000/year/patient). Because
of these problems, it is essential to develop small
molecule HIV fusion/entry inhibitors targeting
the gp41 fusion intermediate with oral bioavail-
ability and low production cost.10,20,21
ADS-J1 is the first small molecule HIV fusion/
entry inhibitor identified with a molecular model-
ing-based virtual screening in combination with a
sandwich enzyme-linked immunosorbent assay
using the NHR-peptide N36, the CHR-peptide
C34, and a conformation-specific monoclonal an-
tibody, NC-1.61,62 ADS-J1 inhibits HIV-1-mediated
membrane fusion and HIV-1 replication with IC50
in the low μM range.63 Computer-aided molecu-
lar docking analysis suggested that ADS-J1 is 
able to dock into the deep hydrophobic pocket
on the gp41 N-helix trimer through the interac-
tion between hydrophobic groups (phenyl and
naphthalene) of ADS-J1 and the hydrophobic
residues in the pocket. Furthermore, one of the
sulfonic acid groups of ADS-J1 is in close prox-
imity to a basic residue (K574) in the pocket re-
gion of the NHR domain. Binding of ADS-J1 to
K574 may block the interaction between the
K574 in NHR and the D632 in CHR in the viral
gp41 to form a salt bridge, which is important 
for the stability of the fusion-active gp41
core.17,18,27,64–66 Although ADS-J1 possesses prop-
erties as an HIV fusion/entry inhibitor targeting
gp41, it is not an ideal lead for drug development
since it contains several sulfonic acid groups 
and an azo group that may potentially induce 
tumorigenesis.
We then screened a chemical library consist-
ing of 33,040 “drug-like” compounds using a
florescent-linked immunosorbent assay-based
high-throughput screening assay and identified
two N-substituted pyrroles, NB-2 and NB-64,
which have potent anti-HIV-1 activities.67 These
compounds inhibited infection by both labora-
tory-adapted and primary HIV-1 strains with dis-
tinct genotypes (clades A to G and group O) and
phenotypes (R5, X4, and R5X4) at low μM levels.
Furthermore, both NB-2 and NB-64 effectively in-
hibited HIV-1 Env-mediated cell-cell fusion. They
interfere with the gp41 conformational changes by
blocking the formation of the fusion-active gp41 
6-HB.67 Computer-aided molecular docking analy-
sis has shown that both compounds fit inside the
hydrophobic pocket, and their -COOH group in-
teracts with a positively charged residue (K574)
around the pocket to form a salt bridge, thereby
blocking the formation of the 6-HB and ultimately
inhibiting HIV-1-mediated membrane fusion. 
The -COOH group in NB-2 and NB-64 is critical to
their inhibitory activities since NB-177 and NB-
178 which have the same structure as NB-2 and
NB-64, respectively, but lack the -COOH group
have no anti-HIV-1 activities.
Based on the structures of NB-64, Xie and 
colleagues recently designed and synthesized 42
N-carboxyphenylpyrrole derivatives in two cate-
gories (A and B series). We tested these com-
pounds and found that 11 of them exhibited
promising anti-HIV-1 activity, which is correlated
with their inhibitory activities on gp41 6-HB 
formation, suggesting that these compounds
block HIV fusion and entry by disrupting gp41
core formation. The most active compound, N-
(3-carboxy-4-hydroxy)phenyl-2,5-dimethylpyr-
role (A12) (Figure 2), could inhibit HIV-1 IIIB
infection with IC50 of 0.69 μM. The molecular
docking analysis has revealed that the carboxyl
group of A12 could interact with either K574 or
R579 in the gp41 NHR to form salt bridges and
that two methyl groups on the pyrrole ring are
HIV-1 gp41 fusion intermediate
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favorable for interaction with the hydrophobic
residues in the gp41 pocket.68 Like NB-2 (molecu-
lar weight = 231) and NB-64 (molecular weight =
222), A12 is also a low molecular size compound
(molecular weight=231). Therefore, it only par-
tially occupies the deep hydrophobic pocket,
which can hold a molecule of > 600 dalton.17 We
therefore proposed that enlarging the molecular
size of A12 may improve its binding affinity and
anti-HIV-1 activity.
Accordingly, we designed a series of 2-aryl-
5-(4-oxo-3-phenethyl-2-thioxothiazolidin-
ylidenemethyl) furans with larger molecular size
(437–515). Computer-based molecular docking
Figure 2. Chemical structures of the small molecule anti-HIV compounds targeting the gp41 fusion intermediate.
SO3H SO3H
OH N
N
OMe
OMe
N
H
N
N
H
N HN
HNN
N
NS
N
F
F F
O O
O
O
O
N
O
O
O
OH
F
F
F
F
C7-Mn34-Mn42
(IC50: undetectable)
Terphenyl derivative 1a
(IC50: ∼ 45 μM)
11
(IC50: ∼ 8 μM)
5M038
(IC50: 10 μM)
NB-2
(IC50: 1.04 μM)
N
HOOC
CI
N
HO
COOH
NB-64
(IC50: 2.21 μM)
NB-293
(IC50: 0.04 μM)
A12
(IC50: 0.69 μM)
2261
(IC50: 11.30 μM)
ADS-J1
(IC50: 8.29 μM)
HN
N
N
N N
HN
N
OH
HO
O
OHO
OH
OH
O
O
O
O
O
O
H3C
H3C CH3
N O
OH OHO
O
S
COOH
H3C CH3
O2N
SO3H
SO3H
analysis indicates that these compounds could
occupy most of the space in the deep hydropho-
bic pocket on the gp41 NHR-trimer. Katritzky and
colleagues synthesized 15 compounds (11a-o) 
of this series by Suzuki-Miyaura cross coupling
and Knoevenagel condensation. We tested these
compounds for their anti-HIV-1 activity and
found that all 15 compounds had improved anti-
HIV-1 activity. One of these compounds, NB-
293, inhibited infection by the laboratory HIV-1
strain IIIB and a primary HIV-1 isolate 94UG103
with IC50 of 44 nM and 74 nM, respectively, > 20-
fold more potent than NB-2, NB-64, and A12,69
suggesting that this compound can serve as a
lead for development of novel small molecule
HIV fusion inhibitors targeting the gp41 fusion
intermediate.
At the same time, several other groups have
also put extensive effort into the search for lead
compounds that target the gp41 NHR-trimer, es-
pecially the pocket region. Harrison’s group at
Harvard University used a structure-based com-
binatorial approach to screen a biased combinato-
rial library consisting of 61,275 compounds, each
of which was linked to the N-terminal residue of
a CHR-peptide P30 (a.a. 636–665) that lacks the
PBD. They found one hybrid molecule, C7-
Mn34-Mn42-P30, with HIV-1 fusion inhibitory
activity about 20-fold over the P30 peptide alone.70
However, the small non-peptide moiety itself
(C7-Mn34-Mn42) has no detectable anti-HIV-1
activity, although it could bind to the hydropho-
bic pocket on the gp41 NHR-trimer as shown by
X-ray crystallography68 (Figure 2). Its low bind-
ing affinity to the gp41 hydrophobic pocket may
be attributed to its inability to inhibit HIV-1 in-
fection. Later, the same group screened several li-
braries consisting of 34,800 small molecules
(< 500) with a high-throughput screening assay
using gp41-5, a soluble single-chain protein with
a structure similar to 5-helix,58 as a target and 
a fluorescein-labeled CHR-peptide C38 as a lig-
and. They identified four compounds that com-
pletely block fluorescein-labeled C38 binding
with gp41-5 to form 6-HB. Three of these active 
compounds contain a 2,4-bis(trifluoromethyl)
[1,2,4] triazolo[4,3-a][1,8] naphthyridine ring,
but only one of them, 5M038 (Figure 2), had suf-
ficient solubility and inhibitory activity against
HIV-1 Env-mediated cell-cell fusion (IC50 =38 μM)
and infection by laboratory-adapted and primary
HIV-1 isolates (IC50 = 19–70 μM) with selectivity
index ≈ 2.
Hamilton and colleagues at Yale University de-
signed four Tris-functionalized 3,2’,2’’-terphenyl
derivatives as the proteomimetics that mimic the
side chains of an i, i + 4, i + 7 dad hydrophobic
surface of the pocket on the gp41 NHR-trimer.
We tested these compounds and found that the
terphenyl derivative 1a could inhibit the gp41 
6-HB formation with an IC50 of 13.18 μg/mL and
inhibit HIV-1-mediated cell-cell fusion (IC50 =
15.7 μg/mL).71
Janda and colleagues at the Scripps Research
Institute synthesized a number of small-molecule
libraries that can disrupt a number of biologically
relevant protein-protein interactions. These li-
brary members are designed upon planar motif 
appended with a variety of chemical functions,
which were termed “credit-card” structures. We
screened two of the “credit-card” libraries for their
inhibitory activity against the HIV-1 gp41 fuso-
genic 6-HB core formation, and cell-cell fusion.
We that the compound 2,261 (Figure 2) is the
most compound with IC50 of 11.3 μM for inhibit-
ing HIV-1 IIIB infection and an selectivity index
of 4.2.72
After screening a small peptidomimetic li-
brary consisting of 200 compounds with a fluo-
rescence quenching assay using a metal-ligated
dye-conjugated NHR-peptide and a fluorophore-
labeled CHR-peptide, which can form 6-HB in
liquid,73 Cai et al identified three new low-
molecular-weight compounds that could inhibit
the gp41 6-HB formation.74 The best compound
is 11 (Figure 2) which inhibits HIV-1 Env-medi-
ated syncytium-formation in the low μM range
(IC50 ∼ 8 μM).7,12 Although these compounds
lack potent anti-HIV-1 activity, they provide new 
molecular scaffolds for the development of HIV
fusion/entry inhibitors targeting the gp41 fusion-
intermediate.
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HIV Fusion/Entry Inhibitor-based
Combination Therapy
Using antiretroviral drugs with different targets
in combination is able to increase the antiviral
potency because of the synergistic effect resulting
from the combination, reduce adverse effects
and delay the emergence of drug resistance.75 It is
well known that combining HIV-1 entry inhibitors
targeting gp120 (e.g. PRO 542), gp41 (e.g. T20),
and the coreceptor, CXCR4 (e.g. AMD3100) or
CCR5 (e.g. SCH-C) exhibits strong synergistic
anti-HIV-1 activity.76–78 We therefore proposed
that combining HIV fusion/entry inhibitors tar-
geting different sites in the gp41 fusion interme-
diate could also result in a similar phenomenon.
Consequently, we first tested the combination of
T20, which contains an HR-binding sequence
and LBD, with Sifuvirtide that consists of the
PBD and an HR-binding sequence (Figure 1). We
found that this combination indeed exhibited
strong synergic antiviral activity against both 
laboratory-adapted and primary HIV-1 strains.79
Then, we tested the combinations of T20, the
first generation HIV fusion inhibitor, with T1249
and T1144, the second and third generation HIV
fusion inhibitors, respectively, against HIV-1-
induced cell-cell fusion. Very surprisingly, dou-
ble combination of T20 with T1249 or T1144
leads to highly potent synergism with two orders
of dose reduction, while triple combination
(T20 + T1249 + T1144) exhibits exceptional syn-
ergistic effect with three orders of dose reduc-
tion. Strong synergism was also observed in the
combinations of T20 with T1249 and/or T1144
against infection by both laboratory-adapted
strains and primary HIV-1 isolates. Strikingly,
combining T20 with T1249 and/or T1144 leads to
strong synergism against infection by T20- and
T1249-resistant variants.80
Previous in vitro and in vivo studies have
demonstrated that the GIV motif in the gp41
NHR region is the primary determinant of HIV-1
resistance to T20.31,33,34,81–88 Mutations in GIV
motif may significantly affect the binding of T20
to the viral gp41 NHR domain, resulting in the
increased resistance of the mutant viruses to
T20.81,89 Unlike T20, both T1249 and T1144 
have a primary binding site in the hydrophobic
pocket on the gp41 NHR-trimer. Therefore, the
mutations in the GIV motif in the viral gp41
NHR region may have much less effect on the
binding of T1249 and T1144 to the viral gp41 NHR
than that of T20. Therefore, the combination of
T1249 or T1144 with T20 may overcome the 
T20-resistance of the mutant viruses. Because T20,
T1249 and T1144 contain different functional
domains and have distinct primary binding sites
in the gp41 fusion intermediate, binding of one
CHR-peptide to the viral gp41 NHR domain may
extend the temporal window period of the fusion
intermediate, which would then become more 
accessible to other CHR-peptides, resulting in 
synergistic effect against HIV-1 infection.80 These
findings suggest a new therapeutic strategy for
treatment of HIV/AIDS patients who have failed
to respond to the first generation HIV fusion in-
hibitor or other anti-HIV drugs targeting different
steps of HIV replication cycle.
Concluding Remarks
Since the discovery of the peptidic HIV fusion in-
hibitors in the early of 1990s, a series of anti-HIV
peptides and small molecule compounds targeting
the gp41 fusion intermediate have been studied.
One of them, T20 has been licensed by the US
FDA for use in clinics to treat HIV-infected pa-
tients who fail to respond to current antiretrovi-
ral therapeutics, while others are in pre-clinical
or clinical development. These studies have 
provided knowledge, techniques, and experience
for development of viral fusion/entry inhibitors
against HIV and other viruses with class I mem-
brane fusion proteins. We are the first to show
that combining different generations of HIV fu-
sion/entry inhibitors targeting the distinct target
sites in the gp41 fusion intermediate results in
highly potent synergy, thus providing a new ther-
apeutic strategy for treatment of HIV infection
and other diseases.
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